

Attorney Docket No.: 10328.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Segura et al

Confirmation No: 9630

Serial No.: 10/560,260

Group Art Unit: TBA

Filed: December 9, 2005

Examiner: TBA

For: Antimicrobial Peptides

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts and the Notice to Comply with Sequence Rules
2. Disk Containing Sequence Listing
3. Copy of Notice to Comply with Sequence Rules

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on May 3, 2006.

Julie Tabarovsky
(name of person mailing paper)


(signature of person mailing paper)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Segura et al

Confirmation No: 9630

Serial No.: 10/560,260

Group Art Unit: TBA

Filed: December 9, 2005

Examiner: TBA

For: Antimicrobial Peptides

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

Mail Stop Sequence
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is in response to the Notice to Comply with Sequence Requirements dated March 9, 2006. The Notice stated that the computer readable form that was filed with the application or filed on December 9, 2005 was not the same as the paper copy of the Sequence Listing.

Applicants therefore enclose another computer readable form of the Sequence Listing. The content of the paper copy that was filed with the application and of the enclosed computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 3, 2006



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/560,260	Dorotea Raventos Segura	10328.204-US

25908
NOVOZYMES NORTH AMERICA, INC.
500 FIFTH AVENUE
SUITE 1600
NEW YORK, NY 10110

INTERNATIONAL APPLICATION NO.

PCT/DK04/00400

I.A. FILING DATE	PRIORITY DATE
06/10/2004	06/11/2003

CONFIRMATION NO. 9630

371 FORMALITIES LETTER



OC000000018228731

Date Mailed: 03/09/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5).

*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/560,260	PCT/DK04/00400	10328.204-US

FORM PCT/DO/EO/922 (371 Formalities Notice)